Testicular Sperm Aspiration (TESA) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Testicular Sperm Aspiration (TESA) is a minimally invasive outpatient procedure for retrieving spermatozoa directly from the testicular parenchyma using a fine needle under local anaesthesia. It is a cornerstone of fertility treatment for men with azoospermia — the complete absence of sperm in the ejaculate — which affects approximately 1% of all men and 10–15% of infertile men.

Azoospermia is classified into two fundamentally different categories. Obstructive azoospermia (OA) occurs when sperm production is normal but transport to the ejaculate is blocked — due to congenital bilateral absence of the vas deferens (CBAVD), vasectomy, epididymal obstruction, or ejaculatory duct obstruction. In OA, sperm can be retrieved from the testis or epididymis in virtually 100% of cases. Non-obstructive azoospermia (NOA) reflects an intrinsic failure of spermatogenesis — due to conditions such as Klinefelter syndrome (47,XXY), Y-chromosome microdeletions, cryptorchidism-related testicular damage, or idiopathic spermatogenic failure — where sperm production is severely reduced or absent. In NOA, retrieval is possible in only 40–60% of men even with the most advanced techniques.

TESA sits within a spectrum of surgical sperm retrieval (SSR) techniques that also includes percutaneous epididymal sperm aspiration (PESA), conventional testicular sperm extraction (TESE), and microdissection TESE (microTESE). The choice of technique depends on the type and severity of azoospermia, institutional expertise, and the outcome of the diagnostic workup. All SSR techniques produce sperm that can only be used in combination with intracytoplasmic sperm injection (ICSI) within an IVF cycle, as retrieved sperm yield is too low and motility too poor for conventional IVF insemination.

Advances in cryobiology allow retrieved testicular sperm to be frozen and stored, enabling decoupling of the sperm retrieval from the female partner's oocyte retrieval, reducing the risk of a failed retrieval coinciding with an expensive IVF cycle.

TESA and related surgical sperm retrieval techniques are indicated for men with confirmed azoospermia or severe sperm dysfunction that cannot be corrected medically.

Obstructive Azoospermia (OA)

• Congenital bilateral absence of the vas deferens (CBAVD): The most common cause of OA in non-vasectomised men; associated with CFTR mutations (the same gene causing cystic fibrosis); male partner must be tested for CFTR mutations and female partner screened before proceeding to IVF/ICSI.
• Vasectomy with failed reversal: Sperm retrieval is the preferred approach when vasectomy reversal (vasovasostomy) has failed or when reversal is declined; TESA/PESA provides sperm for IVF without a second open surgical procedure.
• Epididymal obstruction: Following epididymal trauma, infection (gonorrhoea, chlamydia-related scarring), or idiopathic causes; PESA preferred as the epididymis is the primary site of sperm maturation.
• Ejaculatory duct obstruction: Caused by Mullerian duct cysts, calculi, or post-inflammatory scarring; testicular sperm retrieved by TESA if endoscopic unroofing of the ejaculatory duct is not feasible or fails.

Non-Obstructive Azoospermia (NOA)

• Klinefelter syndrome (47,XXY): The most common chromosomal cause of male infertility; FSH is markedly elevated; focal spermatogenesis may exist in small pockets; microTESE retrieval rate approximately 50–60%.
• Y-chromosome microdeletions (AZFc deletions): Spermatogenic failure; microTESE retrieval rate 50–70% for AZFc deletions; AZFa and AZFb deletions are associated with near-zero retrieval rates and retrieval should not be attempted.
• Idiopathic NOA / maturation arrest / hypospermatogenesis: Normal testicular volume with severely impaired spermatogenesis of unknown cause; microTESE retrieval rate 40–60%.
• Cryptorchidism-related spermatogenic damage: Undescended testes, even after orchidopexy, may have permanent spermatogenic impairment; retrieval attempted if testicular volume and FSH suggest residual function.

Other Indications

• Retrograde ejaculation: Sperm ejaculated into the bladder rather than forward; if urine sperm recovery fails or sperm quality is poor, testicular sperm retrieval by TESA provides a clean, undamaged sample.
• Spinal cord injury with ejaculatory failure: Penile vibratory stimulation or electro-ejaculation attempted first; TESA used when these fail or produce poor-quality sperm.

Eligibility for TESA and related SSR techniques requires a thorough andrological evaluation to confirm azoospermia, classify its type, and select the most appropriate retrieval technique.

Confirming Azoospermia

• Two separate semen analyses performed after 2–5 days of abstinence, with post-centrifugation pellet examination (WHO 2021 criteria) to exclude cryptozoospermia (very rare sperm visible only after centrifugation).
• If cryptozoospermia is identified, sperm may sometimes be used directly for ICSI after high-speed centrifugation, avoiding surgical retrieval.

Hormonal and Andrological Workup

• FSH, LH, testosterone, prolactin, oestradiol: Markedly elevated FSH (>3x upper limit) strongly suggests NOA; normal FSH does not exclude NOA but is more consistent with OA.
• Testicular volume: Measured by Prader orchidometer or scrotal ultrasound; normal volume (15–25 mL) with normal FSH suggests OA; small testes (<10 mL) with high FSH suggests NOA.
• Scrotal ultrasound: Identifies varicocele, epididymal obstruction, intratesticular lesions, and testicular microlithiasis; may visualise dilated efferent ductules in epididymal obstruction.

Genetic Evaluation

• Karyotype (lymphocyte chromosome analysis): Mandatory in all NOA patients; identifies Klinefelter syndrome (47,XXY) and structural chromosomal abnormalities.
• Y-chromosome microdeletion panel (AZFa, AZFb, AZFc): Required in all NOA patients; AZFa and AZFb deletions predict zero sperm retrieval — patients should be counselled that SSR is unlikely to succeed and sperm donation discussed; AZFc deletions have a reasonable retrieval rate.
• CFTR mutation analysis: Mandatory in CBAVD; both male and female partners must be tested before proceeding to IVF/ICSI, as a CFTR carrier female partner combined with a CBAVD-affected male has a 25% chance of a cystic fibrosis-affected child per conception.

Female Partner Evaluation

TESA/IVF/ICSI is a joint couple's undertaking. Female partner evaluation — ovarian reserve (AMH, antral follicle count), uterine anatomy, and cycle regularity — must be completed before SSR is scheduled, and IVF stimulation should be synchronised with the SSR or the cryopreserved sample used in a subsequent thaw cycle.

Several SSR techniques exist, each with different levels of invasiveness, anaesthetic requirements, tissue damage, and sperm retrieval rates. The choice is guided by the azoospermia type and clinical context.

TESA (Testicular Sperm Aspiration)

A 23-gauge butterfly needle is inserted percutaneously into the testicular parenchyma under local anaesthesia (1% lignocaine scrotal block). Negative pressure is applied with a 20 mL syringe while the needle is moved in a fanning motion to maximise tissue sampling. Aspirated seminiferous tubule fragments are immediately examined under an inverted light microscope by an embryologist; the sample is processed for ICSI if sperm are identified. The procedure takes 15–20 minutes. Multiple punctures on both testes are performed if initial aspiration is negative. TESA is highly effective in OA (>95% retrieval rate) and moderately effective in NOA (30–50%), but the non-selective blind sampling misses the focal areas of active spermatogenesis that microTESE specifically targets.

PESA (Percutaneous Epididymal Sperm Aspiration)

A butterfly needle is inserted directly into the epididymis (caput, corpus, or cauda) under local anaesthesia. Abundant, mature sperm are typically retrieved from the epididymis in OA, providing excellent sperm quality for ICSI. PESA is preferred over TESA in OA with a palpable, patent epididymis as the epididymal sperm have undergone maturation. Not applicable in NOA. Procedure time: 10–20 minutes. Can be performed alongside the female partner's egg collection on the same day if fresh sperm is preferred.

Conventional TESE (Testicular Sperm Extraction)

A small open surgical incision is made in the tunica albuginea (the fibrous outer layer of the testis) under general or regional anaesthesia, and a small piece of testicular tissue (5–10 mg) is excised for sperm identification and extraction in the embryology laboratory. Single or multiple biopsies from different areas of both testes increase yield. Conventional TESE retrieves sperm in 20–30% of NOA patients and virtually 100% of OA patients. Higher tissue damage than TESA but lower than multiple percutaneous passes in a blind technique.

Microdissection TESE (microTESE)

The gold standard for NOA. Performed under general anaesthesia through a wide equatorial incision exposing the full testicular parenchyma. An operating microscope (16–25x magnification) allows the surgeon to identify and selectively excise dilated seminiferous tubules — which appear larger, whiter, and more opaque — indicating the foci of active spermatogenesis within an otherwise atrophic testis. MicroTESE doubles the sperm retrieval rate in NOA (40–60%) compared with conventional TESE (20–30%), while removing significantly less testicular tissue (<2 mg vs 200–400 mg in conventional TESE), thereby minimising the risk of testosterone-reducing testicular damage. Developed by Dr. Peter Schlegel at Weill Cornell Medicine in 1999.

Cryopreservation of Retrieved Sperm

Retrieved testicular or epididymal sperm can be cryopreserved (frozen in liquid nitrogen at -196°C) and thawed for use in future IVF/ICSI cycles. This decouples the stressful sperm retrieval procedure from the female partner's oocyte retrieval, allows multiple IVF cycles from a single retrieval, and eliminates the risk of a failed retrieval on egg collection day. Cryopreserved testicular sperm produce equivalent fertilisation and pregnancy rates to fresh testicular sperm (ICSI fertilisation rates: 60–75%; clinical pregnancy rate per cycle: 35–50%).

TESA and related SSR techniques provide men with azoospermia the possibility of biological fatherhood, often representing the only viable pathway to genetic parenthood.

Clinical Benefits

• Enables biological fatherhood in azoospermia: Without SSR, men with azoospermia have no route to biological paternity. TESA/ICSI provides a pathway that achieves clinical pregnancy rates of 35–50% per IVF cycle in appropriately selected couples, comparable to IVF with ejaculated sperm in men with normal semen parameters.
• Minimally invasive (TESA/PESA): Local anaesthesia, 15–20 minute procedure, day-case, minimal tissue damage, rapid recovery; the patient can return to desk work within 24–48 hours.
• MicroTESE doubles NOA retrieval rate: Compared with conventional TESE, microTESE achieves 40–60% sperm retrieval in NOA — including in patients with Klinefelter syndrome and AZFc deletions who have previously been told that fatherhood is impossible.
• Sperm cryopreservation: A single microTESE can provide sperm for multiple IVF cycles, amortising the surgical morbidity and cost over several treatment attempts.
• Minimal impact on testosterone production: When performed correctly by experienced surgeons, TESA and microTESE cause minimal disruption to Leydig cell function. Studies show no significant long-term reduction in serum testosterone after microTESE in most patients.
• Excellent fertilisation rates: ICSI with testicular sperm achieves fertilisation rates of 60–75% per mature oocyte, not significantly different from ejaculated sperm in most reported series.

Psychological Benefits

For couples for whom biological children are a strong priority, a successful sperm retrieval is a critical psychological milestone. The knowledge that the male partner's genetic material can contribute to the pregnancy substantially reduces the psychological burden of infertility and the need to consider sperm donation.

SSR procedures carry a risk profile that varies substantially by technique. TESA has the lowest risk; microTESE carries higher but still manageable risks.

Procedural Risks

• Scrotal haematoma: The most common complication; occurs in less than 1% after TESA, 3–5% after conventional TESE, and 1–2% after microTESE in experienced hands; managed conservatively with ice packs and scrotal support; rarely requires surgical evacuation.
• Orchialgia (testicular pain): Temporary discomfort is almost universal; significant pain lasting more than 2 weeks occurs in 5–10%; managed with NSAIDs; severe or prolonged pain warrants ultrasound to exclude haematoma or torsion.
• Infection / epididymo-orchitis: Rare (<1%) with sterile technique; prophylactic oral antibiotics (ciprofloxacin) routinely prescribed for 3–5 days post-procedure; manifests as fever, scrotal swelling, and tenderness.
• Testicular atrophy: The most serious long-term risk; very rare after single TESA (<0.5%); reported in 1–2% after multiple conventional TESE procedures; microTESE minimises tissue disruption and associated vasculature injury, reducing atrophy risk compared with conventional TESE that removes larger tissue volumes.
• Testosterone decline: Transient reduction in serum testosterone is common after conventional TESE (30–40% of patients show >25% reduction at 3 months); returns to baseline in 90% by 6–12 months; permanent hypogonadism rare with microTESE when performed by experienced surgeons.

Retrieval Failure

• The most distressing outcome is failure to retrieve sperm. In OA this is exceedingly rare (<1–2%); in NOA, 40–60% of patients do not have retrievable sperm even with microTESE. Couples must be counselled on this possibility before SSR, and the alternative of sperm donation should be discussed proactively.

IVF/ICSI-Related Risks

• Ovarian hyperstimulation syndrome (OHSS) in the female partner; multiple gestation; ICSI failure (no fertilisation); embryo arrest before transfer; implantation failure. These risks are inherent to the IVF process and managed by the fertility unit's clinical team.

Recovery from TESA is rapid. MicroTESE requires a few more days of restricted activity due to the larger surgical dissection.

Immediate Post-Procedure Care

• Scrotal support and ice packs: Applied continuously for the first 48 hours to minimise swelling and haematoma risk.
• Pain management: Paracetamol 1 g every 6 hours and ibuprofen 400 mg three times daily for 3–5 days (if no contraindication); opioids are rarely required after TESA; more commonly used after microTESE for the first 24–48 hours.
• Activity restriction: Desk work permitted after 24–48 hours (TESA) or 3–5 days (microTESE); avoidance of strenuous physical activity, cycling, and sexual intercourse for 1 week (TESA) or 2 weeks (microTESE).
• Wound care (microTESE): The scrotal incision is closed with absorbable sutures; wound kept dry for 48–72 hours; no dressings change required; sutures dissolve spontaneously within 2–3 weeks.

Follow-Up Assessments

• Clinical review at 1–2 weeks: Wound inspection, pain and swelling assessment, ultrasound if haematoma suspected.
• Hormonal reassessment at 3 months: Serum testosterone, FSH, and LH measured to detect any procedure-related endocrine change, particularly after microTESE in Klinefelter and NOA patients.
• Semen analysis at 3 months: In patients who retain some spermatogenic function, to confirm that TESA/microTESE has not further reduced ejaculate sperm count.

IVF/ICSI Coordination

If cryopreserved sperm are being used, the IVF cycle can proceed independently of the SSR procedure. The fertility clinic's embryology team coordinates thaw quality assessment, ICSI procedure, embryo culture (blastocyst on Day 5), and frozen embryo transfer. Preimplantation genetic testing (PGT-A for aneuploidies; PGT-M for monogenic disorders such as cystic fibrosis in CBAVD couples) may be offered to screen embryos before transfer.

The cost of TESA and related SSR procedures varies substantially by technique, setting, and whether costs are bundled with the IVF/ICSI cycle.

Procedure Costs by Technique

• TESA / PESA: The lowest-cost option; typically $500–$1,500 in the USA as a standalone procedure; $100–$400 at specialist fertility centres in India and Thailand.
• Conventional TESE: $1,500–$3,500 in the USA (operating room, general anaesthesia, pathology and embryology laboratory); $300–$800 in India.
• Microdissection TESE (microTESE): The most expensive SSR technique, reflecting operative microscope use, longer surgical time (2–3 hours), and specialised urological expertise; $3,000–$8,000 in the USA; $800–$2,500 in specialist centres in India, South Korea, and Thailand.

IVF/ICSI Cycle Costs

SSR must always be considered alongside IVF/ICSI costs, as retrieved sperm cannot be used for natural conception. A single IVF/ICSI cycle in the USA costs $12,000–$20,000 including medications; in India $2,000–$5,000; in Spain and Czech Republic $4,000–$8,000. Multiple cycles are frequently needed, significantly increasing total treatment cost.

Additional Cost Factors

• Sperm cryopreservation and storage: $500–$1,500 for initial freeze and processing; $200–$600/year for liquid nitrogen storage.
• Genetic testing: Karyotype, Y-microdeletion, and CFTR testing add $300–$1,000 to the workup cost but are essential for informed decision-making.
• Embryo cryopreservation and frozen embryo transfer (FET): Additional $3,000–$5,000 in the USA per FET cycle if surplus embryos are banked for future use.
• International medical tourism: Couples travelling to India, Thailand, Spain, or the Czech Republic can access equivalent SSR and IVF/ICSI technology at 30–60% of USA or UK costs, often with shorter waiting times.

Several alternatives to TESA exist depending on the cause of azoospermia, patient preferences, and clinical circumstances.

Surgical Alternatives

• Vasectomy reversal (vasovasostomy / vasoepididymostomy): In men with obstructive azoospermia due to vasectomy, surgical reversal restores the natural vas deferens continuity. Success rates for natural pregnancy are 60–90% if performed within 10 years of vasectomy, declining to 30–50% after 15+ years as epididymal obstruction develops. Reversal avoids repeated IVF costs but requires a technically demanding microsurgical procedure and 6–18 months wait for natural conception attempts.
• Endoscopic ejaculatory duct resection (TUNED/TURED): For ejaculatory duct obstruction; endoscopic unroofing restores natural ejaculation in 50–65% of cases; attempted before SSR in appropriate anatomy.

Medical Treatment

• Hormonal therapy for hypogonadotropic hypogonadism (HH): Men with low FSH, LH, and testosterone due to hypothalamic or pituitary dysfunction (secondary hypogonadism) may respond to gonadotrophin stimulation (hCG + FSH injections or pulsatile GnRH); this can restore spermatogenesis and natural fertility without SSR, making it the preferred first-line treatment before invasive retrieval in HH.
• Empirical medical therapy for NOA: Antioxidants, clomiphene citrate, letrozole, anastrozole — evidence base is limited; may improve sperm retrieval rates modestly in selected NOA patients and some centres use these before microTESE.

Donor Sperm

• When SSR fails or is declined, donor sperm insemination (IUI or IVF/ICSI with donor sperm) offers pregnancy rates equivalent to treatment with a partner who has normal semen parameters. Donor sperm from accredited sperm banks undergo thorough genetic, infectious disease, and phenotypic screening. Psychological counselling for both partners is recommended before proceeding to donor sperm treatment.

Adoption and Child-Free Living

For couples who do not wish to pursue SSR, IVF, or donor sperm, adoption and child-free living are valid life choices that should be presented without judgment as part of comprehensive infertility counselling.